Item 7.01Regulation FD Disclosure

On August 7, 2020, Eastman Kodak Company (the "Company") announced that it had formed a special committee (the "Special Committee") to oversee an internal review of recent activity by the Company and related parties in connection with the announcement of a potential loan by the U.S. International Development Finance Corporation to support the launch of Kodak Pharmaceuticals, and that the Special Committee had retained Akin Gump Strauss Hauer & Feld LLP ("Akin Gump") to conduct this review. On September 15, 2020, the Special Committee issued a press release announcing that it completed this review and that Akin Gump had delivered a report to the Special Committee in connection with this review (the "Report"). On September 15, 2020, the Company issued a press release confirming its receipt and acceptance of the findings and recommendations of the Report.

A copy of the Press Release issued by the Special Committee is furnished as Exhibit 99.1 hereto. A copy of the Press Release issued by the Company is furnished as Exhibit 99.2 hereto. A copy of the Report is furnished as Exhibit 99.3 hereto. This Item 7.01 and Exhibits 99.1, 99.2 and 99.3 (the "Furnished Information") are being furnished and shall not be deemed "filed" for any purpose. The Furnished Information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to the Furnished Information in such filing.

Item 9.01Financial Statements and Exhibits



(d)    Exhibits (all furnished and not filed)
(99.1)   Press release issued on September 15, 2020 by the Special Committee
(99.2)   Press release issued on September 15, 2020 by the Company
(99.3)   Report delivered by Akin Gump





                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses